Non-invasive glioblastoma immunoprofiling by printed peptide arrays
Immune monitoring assays for patient stratification and treatment efficacy in clinical trials are in demand. We have recently described a cost-effective non-invasive assay to determine the immune status of glioblastoma patients. Profiling antitumor serum antibodies by customized printed peptide arra...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 Feb 2016
|
| In: |
OncoImmunology
Year: 2016, Jahrgang: 5, Heft: 2 |
| ISSN: | 2162-402X |
| DOI: | 10.1080/2162402X.2015.1069941 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/2162402X.2015.1069941
|
| Verfasserangaben: | Andreas Mock and Christel Herold-Mende |
| Zusammenfassung: | Immune monitoring assays for patient stratification and treatment efficacy in clinical trials are in demand. We have recently described a cost-effective non-invasive assay to determine the immune status of glioblastoma patients. Profiling antitumor serum antibodies by customized printed peptide arrays identified response against a tenascin-C (TNC) peptide as a robust prognostic biomarker. |
|---|---|
| Beschreibung: | Gesehen am 10.07.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 2162-402X |
| DOI: | 10.1080/2162402X.2015.1069941 |